Back to top
more

Cronos Group (CRON)

(Real Time Quote from BATS)

$1.96 USD

1.96
2,314,721

+0.01 (0.51%)

Updated Aug 4, 2025 09:32 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 246)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Sweta Killa headshot

Cannabis ETFs Spike on Jazz-GW Pharma Deal

by Sweta Killa

Jazz Pharmaceuticals (JAZZ) agreed to buy cannabinoid drug company GW Pharmaceuticals (GWPH) for $7.2 billion in cash and stock that has strengthened the bullish case for the cannabis industry.

Zacks Equity Research

The Zacks Analyst Blog Highlights: IIPR, CRON, CGC and STZ

by Zacks Equity Research

The Zacks Analyst Blog Highlights: IIPR, CRON, CGC and STZ

Nitish Marwah headshot

4 Stocks to Ride the Wave of Cannabis Legalization

by Nitish Marwah

Increasing tolerance, financial protection, credit availability, and legal votes have shaped America's hemp industry lately.

Nitish Marwah headshot

4 Stocks to Ride the Wave of Cannabis Legalization

by Nitish Marwah

Increasing tolerance, financial protection, credit availability, and legal votes have shaped America's hemp industry lately.

Neena Mishra headshot

Should You Buy Cannabis Stocks & ETFs Now?

by Neena Mishra

CNBC's cannabis expert Tim Seymour discusses the recent developments in the space.

Zacks Equity Research

Cronos Group (CRON) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Cronos (CRON) delivered earnings and revenue surprises of 33.33% and 4.88%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Neena Mishra headshot

Why Cannabis Stocks & ETFs Are Soaring

by Neena Mishra

Marijuana stocks are rising on hopes of favorable regulatory environment

Zacks Equity Research

Analysts Estimate Cronos Group (CRON) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Cronos (CRON) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Zacks Market Edge Highlights: Aurora Cannabis, Canopy Growth, Cronos Group, Innovative Industrial Properties and Constellation Brands

by Zacks Equity Research

Zacks Market Edge Highlights: Aurora Cannabis, Canopy Growth, Cronos Group, Innovative Industrial Properties and Constellation Brands

Tracey Ryniec headshot

Is it Finally Time to Buy Marijuana Stocks?

by Tracey Ryniec

With new states set to legalize cannabis this November, and the possibility of federal legalization looming, will the marijuana stocks finally live up to the hype?

Zacks Equity Research

Company News for Aug 7, 2020

by Zacks Equity Research

Companies In The News: BMY, CRON, BDX, LNG.

Zacks Equity Research

Cronos Group (CRON) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Cronos (CRON) delivered earnings and revenue surprises of -216.67% and 16.96%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Analysts Estimate Cronos Group (CRON) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Cronos (CRON) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Cronos (CRON) to Report Q2 Earnings: What's in the Offing?

by Zacks Equity Research

Investors will focus on regular top and bottom-line numbers along with its pipeline progress, when Cronos (CRON) reports Q2 results.

Neena Mishra headshot

Is it Time to Buy Cannabis Stocks & ETFs?

by Neena Mishra

CNBC's cannabis expert Tim Seymour discusses the outlook for the industry.

Zacks Equity Research

Is Cronos Group (CRON) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Is (CRON) Outperforming Other Medical Stocks This Year?

Zacks Equity Research

Cronos Group's Shares March Higher, Can It Continue?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Cronos Group.

Zacks Equity Research

Cronos (CRON) Looks Good: Stock Adds 8.1% in Session

by Zacks Equity Research

Cronos (CRON) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

Benjamin Rains headshot

Find Stocks Under $10 to Buy Amid Coronavirus Economic Reopening

by Benjamin Rains

We screened for strong 'cheap' stocks that are trading under $10 a share that investors might want to buy as the market rally continues...

Zacks Equity Research

Cronos Group (CRON) Beats Q1 Earnings Estimates

by Zacks Equity Research

Cronos (CRON) delivered earnings and revenue surprises of 385.71% and -21.68%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Cronos (CRON) to Report Q1 Earnings: What's in the Offing?

by Zacks Equity Research

Investors will focus on regular top and bottom-line numbers along with its pipeline progress, when Cronos (CRON) reports Q1 results.

Zacks Equity Research

Earnings Preview: Cronos Group (CRON) Q1 Earnings Expected to Decline

by Zacks Equity Research

Cronos (CRON) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Cronos Group (CRON) Gains As Market Dips: What You Should Know

by Zacks Equity Research

Cronos Group (CRON) closed at $5.52 in the latest trading session, marking a +1.85% move from the prior day.

Zacks Equity Research

Cronos Group (CRON) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Cronos (CRON) delivered earnings and revenue surprises of -75.00% and -36.86%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Here's How Coronavirus Can Impact Cannabis Industry

by Zacks Equity Research

Marijuana should be avoided during the pandemic as users share marijuana joints, which may increase the spread of the virus.